Statement on Expanded Access
Verastem Oncology is a biopharmaceutical company committed to advancing new medicines for patients battling cancer and we are also working to bring these medicines to patients as quickly and safely as possible.
As both of our investigational agents, VS-6766 and defactinib, are in clinical trials to evaluate their efficacy and safety, we are not currently providing access to these therapies outside of clinical trials. At this time, we believe participation in a clinical trial evaluating our investigational therapies is the optimal way to access these investigational therapies and enable thorough evaluation and support regulatory approvals.
These ongoing clinical trials include the Phase 2 registration-directed trials evaluating the combination of VS-6766 alone and with defactinib in patients with recurrent low-grade serous ovarian cancer and in patients with recurrent KRAS-G12V non-small cell lung cancer as part of its RAMP (Raf And Mek Program). More information about these trials is available at www.ramp201study.com and www.ramp202study.com.
Individuals participating in our clinical trials are provided with the treatment being tested. The purpose of these trials is to determine whether the treatment is safe and effective. We submit a full complement of evidence from trials and other data to regulatory authorities, who make the final decision to approve the treatment or not. Until the regulatory authority has made this decision, the treatment remains experimental and not yet available to patients.